查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830718

2025年全球癌症体外诊断（IVD）市场报告

Cancer In Vitro Diagnostics (IVD) Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，癌症体外诊断 (IVD) 市场规模强劲成长，从 2024 年的 133.6 亿美元增加到 2025 年的 143.2 亿美元，复合年增长率为 7.2%。预测期内的增长归因于癌症生物标记研究的兴起、需要诊断测试的癌症临床试验的增加、政府医疗保健计划的扩展、检测基础设施的完善以及生物技术研究资金的增加。

预计未来几年癌症体外诊断 (IVD) 市场规模将强劲成长，到 2029 年将达到 186.2 亿美元，复合年增长率为 6.8%。预测期内的成长可归因于政府和非政府组织主导的癌症筛检计画、人口老化、人们对早期癌症检测的认识不断提高、保险报销范围的扩大以及照护现场(POC) 的普及。这段时期的主要趋势包括液态切片技术的扩展、次世代定序的进步、人工智慧和机器学习的融合、微流体的引入以及数位病理解决方案的采用。

体外癌症诊断 (IVD) 是在人类体外对血液、组织或其他体液等样本进行的诊断测试，用于检测、监测和管理癌症。这些测试透过分析生物标记、基因突变和其他癌症相关指标，有助于早期发现、诊断、预后和治疗选择。

该公司在癌症体外诊断 (IVD) 领域的主要产品类型包括试剂和套件、仪器、软体和服务。试剂和套件是即用型化学品和预处理测试材料，用于检测癌症标记和体外诊断 (IVD) 测试中的样本分析。它们采用临床化学、免疫化学、免疫检测、血液学、凝血和止血、微生物学和分子诊断等技术。这些诊断涵盖多种癌症类型，包括乳癌、肺癌、前列腺癌和大肠癌，并服务于医院、实验室、学术机构、就地检验中心和患者自我检测项目等终端用户。

2025年春季美国关税的突然上调及其引发的贸易摩擦严重影响了医疗保健产业，尤其是关键医疗设备、诊断设备和药品的供应。医院和医疗机构面临进口手术器械、影像设备以及注射器和导管等消耗品成本上涨的问题。这些成本上涨给医疗保健预算带来了巨大压力，导致一些医疗机构推迟设备升级或将成本转嫁给患者。此外，原料和零件的关税阻碍了基本药品和医疗设备的生产，造成了供应链瓶颈。为此，该行业正在筹资策略多元化，尽可能促进本地生产，并倡导对紧急医疗产品免关税。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供癌症体外诊断 (IVD) 市场统计数据，例如全球市场规模、区域份额、竞争对手的市场份额、癌症体外诊断 (IVD) 细分市场、市场趋势和机会，以及您在癌症体外诊断 (IVD) 行业取得成功所需的数据。本癌症体外诊断 (IVD) 市场研究报告对该行业的现状和未来趋势进行了详细分析，为您提供所需的一切观点。

癌症发病率的上升预计将推动癌症体外诊断 (IVD) 市场的未来成长。癌症是指体内异常细胞不受控制地增生和扩散，侵入邻近组织并形成肿瘤。由于预期寿命的增加和感染疾病死亡率的降低，越来越多的老年人面临罹癌的高风险。透过对患者样本进行临床测试，癌症体外诊断 (IVD) 可支持疾病的早期发现、监测和管理，从而能够及时做出治疗决策并改善结果。例如，2024 年 2 月，总部位于瑞士的政府间组织世界卫生组织 (WHO) 报告称，预计 2022 年全球新增癌症病例将达到 2,000 万，到 2050 年将增至 3,500 万，增幅为 77%。因此，癌症发生率的上升正在推动癌症体外诊断 (IVD) 市场的成长。

癌症体外诊断 (IVD) 市场的主要企业正专注于技术进步，例如 CE 标誌的体外诊断 (IVD) 癌症检测套组，以提高临床环境中遗传性癌症检测的可及性、准确性和标准化。 CE 标誌的 IVD 癌症检测套组是符合欧盟体外诊断药物指令 (IVDD) 的诊断检测，确保实验室使用的性能、安全性和品质检验。例如，2022 年 2 月，美国基因医学公司 Invitae 在欧洲推出了 FusionPlex Dx 和 LiquidPlex Dx。 FusionPlex Dx 可对 FFPE 样本中的低频变异进行高灵敏度检测，而 LiquidPlex Dx 可从血液中进行非侵入性癌症基因组分析，从而在组织样本有限的情况下促进个人化治疗和疾病监测。

2022年2月，美国医疗科技公司BD（Becton, Dickinson & Company）从西班牙生物技术公司Vitro SA手中收购了Cytognos。 Vitro SA是一家专注于癌症IVD（体外诊断）的生技公司。透过此次收购，BD将把其产品组合从癌症检测和诊断扩展到治疗后监测，从而支持全方位的患者照护。

癌症体外诊断 (IVD) 市场由提供癌症筛检、早期检测、诊断分析和个人化治疗指导等服务的营业单位所获得的收益所构成。市场价值还包括服务提供者销售的或包含在其服务产品中的任何相关产品的价值。癌症体外诊断 (IVD) 市场还包括试剂、检测试剂套件、诊断仪器、分子诊断平台和免疫检测係统的销售。该市场的价值为“出厂价”，即产品製造商或创造者向其他营业单位（包括下游製造商、批发商、经销商和零售商）或直接向最终客户销售的产品价值。该市场中的产品价值还包括产品创造者销售的任何相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球体外肿瘤诊断 (IVD)：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球体外癌症诊断（IVD）市场：成长率分析
  • 全球体外癌症诊断 (IVD) 市场表现：规模与成长，2019-2024 年
  • 全球体外癌症诊断 (IVD) 市场预测：2024-2029 年及 2034 年规模与成长
  • 全球癌症体外诊断（IVD）：总目标市场（TAM）

第六章 市场细分

  • 全球癌症体外诊断 (IVD) 市场（依产品类型、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 试剂和套件
  • 装置
  • 软体和服务
  • 全球癌症体外诊断 (IVD) 市场技术、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 临床化学
  • 免疫化学或免疫检测
  • 血液学
  • 凝血和止血
  • 微生物学
  • 分子诊断
  • 其他技术
  • 全球癌症体外诊断 (IVD) 市场（按癌症类型、表现和预测），2019-2024 年、2024-2029 年、2034 年
  • 乳癌
  • 肺癌
  • 摄护腺癌
  • 大肠直肠癌
  • 全球体外癌症诊断 (IVD) 市场（按最终用户、绩效和预测），2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 研究所
  • 学术的
  • 就地检验
  • 患者自我检查
  • 其他最终用户
  • 全球体外癌症诊断 (IVD) 市场：按试剂和套件（按类型）细分、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • PCR试剂和套件
  • NGS试剂和套件
  • 免疫检测试剂和套件
  • 原位杂交 (ISH) 试剂和套件
  • 其他的
  • 全球体外癌症诊断 (IVD) 市场：按设备类型、性能和预测细分，2019-2024 年、2024-2029 年、2034 年
  • PCR设备
  • NGS设备
  • 免疫检测分析仪
  • ISH仪器
  • 其他的
  • 全球癌症体外诊断 (IVD) 市场：按软体和服务细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 数据分析软体
  • 实验室资讯管理系统
  • 云端基础的资料管理
  • 装置整合软体
  • 支援和维护服务

第七章 区域和国家分析

  • 全球癌症体外诊断 (IVD) 市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球癌症体外诊断 (IVD) 市场：按国家、表现和预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 癌症体外诊断（IVD）市场：竞争格局
  • 癌症体外诊断（IVD）市场：公司简介
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • GE HealthCare Technologies Inc.
  • Hologic Inc.
  • Illumina Inc.
  • bioMerieux SA
  • Sysmex Corporation
  • Exact Sciences Corporation
  • Bio-Rad Laboratories Inc.
  • QIAGEN NV
  • Autobio Diagnostics Co Ltd.
  • Transasia Bio-Medicals Ltd.
  • NanoString Technologies Inc.
  • Genetron Holdings Limited
  • Cancer Diagnostics Inc.
  • J. Mitra & Co. Pvt Ltd.
  • Tulip Diagnostics（P）Ltd.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年癌症体外诊断（IVD）市场：提供新机会的国家
  • 2029年癌症体外诊断（IVD）市场：细分领域带来新机会
  • 2029年癌症体外诊断（IVD）市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r37705

Cancer in vitro diagnostics (IVD) refers to diagnostic tests conducted outside the human body on samples like blood, tissue, or other bodily fluids to detect, monitor, or manage cancer. These tests aid in early detection, diagnosis, prognosis, and treatment selection by analyzing biomarkers, genetic mutations, and other cancer-related indicators.

The primary product types of cancer in vitro diagnostics (IVD) include reagents and kits, instruments, and software and services. Reagents and kits are ready-to-use chemicals and prepared testing materials designed to detect cancer markers and analyze samples in IVD tests. They employ technologies such as clinical chemistry, immunochemistry or immunoassays, hematology, coagulation and hemostasis, microbiology, molecular diagnostics, and others. These diagnostics cover various cancer types, including breast, lung, prostate, and colorectal cancers, and serve end users such as hospitals, laboratories, academic institutions, point-of-care testing centers, and patient self-testing programs.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The cancer in vitro diagnostics (IVD) market research report is one of a series of new reports from The Business Research Company that provides cancer in vitro diagnostics (IVD) market statistics, including cancer in vitro diagnostics (IVD) industry global market size, regional shares, competitors with a cancer in vitro diagnostics (IVD) market share, cancer in vitro diagnostics (IVD) market segments, market trends and opportunities, and any further data you may need to thrive in the cancer in vitro diagnostics (IVD) industry. This cancer in vitro diagnostics (IVD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer in vitro diagnostics (IVD) market size has grown strongly in recent years. It will grow from $13.36 billion in 2024 to $14.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising research in cancer biomarkers, increasing number of oncology clinical trials requiring diagnostic testing, expanding government health initiatives, growth in laboratory infrastructure, and increasing funding for biotechnology research.

The cancer in vitro diagnostics (IVD) market size is expected to see strong growth in the next few years. It will grow to $18.62 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to government and NGO-led cancer screening initiatives, an aging population, increasing awareness of early cancer detection, expanded reimbursement coverage, and growing adoption of point-of-care (POC) diagnostics. Major trends during this period include the expansion of liquid biopsy technologies, advancements in next-generation sequencing, integration of artificial intelligence and machine learning, incorporation of microfluidics, and adoption of digital pathology solutions.

The increasing incidence of cancer is expected to propel the growth of the cancer in vitro diagnostics (IVD) market going forward. Cancer refers to the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and form tumors. The rising incidence of cancer is largely driven by the aging population, as longer life expectancy and reduced mortality from infectious diseases result in more elderly individuals, who are at higher risk of developing cancer. Cancer in vitro diagnostics (IVD) support early detection, monitoring, and management of the disease through laboratory tests on patient samples, enabling timely treatment decisions and improved outcomes. For instance, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that new cancer cases globally reached 20 million in 2022 and are projected to rise to 35 million by 2050, representing a 77% increase. Therefore, the rising incidence of cancer is driving the growth of the cancer in vitro diagnostics (IVD) market.

Key companies in the cancer in vitro diagnostics (IVD) market are focusing on technological advancements, such as CE-marked IVD cancer testing kits, to improve accessibility, accuracy, and standardization of hereditary cancer testing across clinical settings. CE-marked IVD cancer testing kits are diagnostic assays compliant with the European Union's in vitro diagnostic directive (IVDD), ensuring validated performance, safety, and quality for laboratory use. For instance, in February 2022, Invitae, a US-based medical genetics company, launched FusionPlex Dx and LiquidPlex Dx in Europe. FusionPlex Dx provides sensitive detection of low-frequency variants in FFPE samples, while LiquidPlex Dx enables non-invasive cancer genomic profiling from blood, facilitating personalized treatment and disease monitoring when tissue samples are limited.

In February 2022, BD (Becton, Dickinson and Company), a US-based medical technology firm, acquired Cytognos from Vitro S.A., a Spain-based biotechnology company specializing in cancer IVD. This acquisition allows BD to expand its portfolio from cancer discovery and diagnosis into post-treatment monitoring, supporting the full spectrum of patient care.

Major players in the cancer in vitro diagnostics (ivd) market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, GE HealthCare Technologies Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Sysmex Corporation, Exact Sciences Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Autobio Diagnostics Co Ltd., Transasia Bio-Medicals Ltd., NanoString Technologies Inc., Genetron Holdings Limited, Cancer Diagnostics Inc., J. Mitra & Co. Pvt Ltd., and Tulip Diagnostics (P) Ltd.

North America was the largest region in the cancer in vitro diagnostics (IVD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer in vitro diagnostics (IVD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cancer in vitro diagnostics (IVD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer in vitro diagnostics (IVD) market consists of revenues earned by entities by providing services such as cancer screening, early detection testing, diagnostic analysis, and personalized treatment guidance. The market value includes the value of related goods sold by the service provider or contained within the service offering. The cancer in vitro diagnostics (IVD) market also includes sales of reagents, assay kits, diagnostic instruments, molecular diagnostic platforms, and immunoassay systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer In Vitro Diagnostics (IVD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer in vitro diagnostics (ivd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer in vitro diagnostics (ivd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer in vitro diagnostics (ivd) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product Type: Reagents And Kits; Instruments; Software And Services
  • 2) By Technology: Clinical Chemistry; Immunochemistry Or Immunoassays; Hematology; Coagulation And Hemostasis; Microbiology; Molecular Diagnostics; Other Technology
  • 3) By Cancer Type: Breast Cancer; Lung Cancer; Prostate Cancer; Colorectal Cancer
  • 4) By End-Users: Hospitals; Laboratories; Academics; Point-Of-Care Testing; Patient Self-Testing; Other End Users
  • Subsegments:
  • 1) By Reagents And Kits: PCR Reagents And Kits; NGS Reagents And Kits; Immunoassay Reagents And Kits; In Situ Hybridization (ISH) Reagents And Kits; Others
  • 2) By Instruments: PCR Instruments; NGS Instruments; Immunoassay Analyzers; ISH Instruments; Others
  • 3) By Software And Services: Data Analysis Software; Laboratory Information Management Systems; Cloud-Based Data Management; Instrument Integration Software; Support And Maintenance Services
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation; Siemens Healthineers AG; GE HealthCare Technologies Inc.; Hologic Inc.; Illumina Inc.; bioMerieux SA; Sysmex Corporation; Exact Sciences Corporation; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Autobio Diagnostics Co Ltd.; Transasia Bio-Medicals Ltd.; NanoString Technologies Inc.; Genetron Holdings Limited; Cancer Diagnostics Inc.; J. Mitra & Co. Pvt Ltd.; Tulip Diagnostics (P) Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer In Vitro Diagnostics (IVD) Market Characteristics

3. Cancer In Vitro Diagnostics (IVD) Market Trends And Strategies

4. Cancer In Vitro Diagnostics (IVD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cancer In Vitro Diagnostics (IVD) Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cancer In Vitro Diagnostics (IVD) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cancer In Vitro Diagnostics (IVD) Market Growth Rate Analysis
  • 5.4. Global Cancer In Vitro Diagnostics (IVD) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cancer In Vitro Diagnostics (IVD) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cancer In Vitro Diagnostics (IVD) Total Addressable Market (TAM)

6. Cancer In Vitro Diagnostics (IVD) Market Segmentation

  • 6.1. Global Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reagents And Kits
  • Instruments
  • Software And Services
  • 6.2. Global Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Clinical Chemistry
  • Immunochemistry Or Immunoassays
  • Hematology
  • Coagulation And Hemostasis
  • Microbiology
  • Molecular Diagnostics
  • Other Technology
  • 6.3. Global Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • 6.4. Global Cancer In Vitro Diagnostics (IVD) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Laboratories
  • Academics
  • Point-Of-Care Testing
  • Patient Self-Testing
  • Other End Users
  • 6.5. Global Cancer In Vitro Diagnostics (IVD) Market, Sub-Segmentation Of Reagents And Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR Reagents And Kits
  • NGS Reagents And Kits
  • Immunoassay Reagents And Kits
  • In Situ Hybridization (ISH) Reagents And Kits
  • Others
  • 6.6. Global Cancer In Vitro Diagnostics (IVD) Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR Instruments
  • NGS Instruments
  • Immunoassay Analyzers
  • ISH Instruments
  • Others
  • 6.7. Global Cancer In Vitro Diagnostics (IVD) Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Analysis Software
  • Laboratory Information Management Systems
  • Cloud-Based Data Management
  • Instrument Integration Software
  • Support And Maintenance Services

7. Cancer In Vitro Diagnostics (IVD) Market Regional And Country Analysis

  • 7.1. Global Cancer In Vitro Diagnostics (IVD) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cancer In Vitro Diagnostics (IVD) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer In Vitro Diagnostics (IVD) Market

  • 8.1. Asia-Pacific Cancer In Vitro Diagnostics (IVD) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer In Vitro Diagnostics (IVD) Market

  • 9.1. China Cancer In Vitro Diagnostics (IVD) Market Overview
  • 9.2. China Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer In Vitro Diagnostics (IVD) Market

  • 10.1. India Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer In Vitro Diagnostics (IVD) Market

  • 11.1. Japan Cancer In Vitro Diagnostics (IVD) Market Overview
  • 11.2. Japan Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer In Vitro Diagnostics (IVD) Market

  • 12.1. Australia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer In Vitro Diagnostics (IVD) Market

  • 13.1. Indonesia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer In Vitro Diagnostics (IVD) Market

  • 14.1. South Korea Cancer In Vitro Diagnostics (IVD) Market Overview
  • 14.2. South Korea Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer In Vitro Diagnostics (IVD) Market

  • 15.1. Western Europe Cancer In Vitro Diagnostics (IVD) Market Overview
  • 15.2. Western Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer In Vitro Diagnostics (IVD) Market

  • 16.1. UK Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer In Vitro Diagnostics (IVD) Market

  • 17.1. Germany Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer In Vitro Diagnostics (IVD) Market

  • 18.1. France Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer In Vitro Diagnostics (IVD) Market

  • 19.1. Italy Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer In Vitro Diagnostics (IVD) Market

  • 20.1. Spain Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer In Vitro Diagnostics (IVD) Market

  • 21.1. Eastern Europe Cancer In Vitro Diagnostics (IVD) Market Overview
  • 21.2. Eastern Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer In Vitro Diagnostics (IVD) Market

  • 22.1. Russia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer In Vitro Diagnostics (IVD) Market

  • 23.1. North America Cancer In Vitro Diagnostics (IVD) Market Overview
  • 23.2. North America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer In Vitro Diagnostics (IVD) Market

  • 24.1. USA Cancer In Vitro Diagnostics (IVD) Market Overview
  • 24.2. USA Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer In Vitro Diagnostics (IVD) Market

  • 25.1. Canada Cancer In Vitro Diagnostics (IVD) Market Overview
  • 25.2. Canada Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer In Vitro Diagnostics (IVD) Market

  • 26.1. South America Cancer In Vitro Diagnostics (IVD) Market Overview
  • 26.2. South America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer In Vitro Diagnostics (IVD) Market

  • 27.1. Brazil Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer In Vitro Diagnostics (IVD) Market

  • 28.1. Middle East Cancer In Vitro Diagnostics (IVD) Market Overview
  • 28.2. Middle East Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer In Vitro Diagnostics (IVD) Market

  • 29.1. Africa Cancer In Vitro Diagnostics (IVD) Market Overview
  • 29.2. Africa Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Cancer In Vitro Diagnostics (IVD) Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer In Vitro Diagnostics (IVD) Market Competitive Landscape And Company Profiles

  • 30.1. Cancer In Vitro Diagnostics (IVD) Market Competitive Landscape
  • 30.2. Cancer In Vitro Diagnostics (IVD) Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis

31. Cancer In Vitro Diagnostics (IVD) Market Other Major And Innovative Companies

  • 31.1. GE HealthCare Technologies Inc.
  • 31.2. Hologic Inc.
  • 31.3. Illumina Inc.
  • 31.4. bioMerieux SA
  • 31.5. Sysmex Corporation
  • 31.6. Exact Sciences Corporation
  • 31.7. Bio-Rad Laboratories Inc.
  • 31.8. QIAGEN N.V.
  • 31.9. Autobio Diagnostics Co Ltd.
  • 31.10. Transasia Bio-Medicals Ltd.
  • 31.11. NanoString Technologies Inc.
  • 31.12. Genetron Holdings Limited
  • 31.13. Cancer Diagnostics Inc.
  • 31.14. J. Mitra & Co. Pvt Ltd.
  • 31.15. Tulip Diagnostics (P) Ltd.

32. Global Cancer In Vitro Diagnostics (IVD) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer In Vitro Diagnostics (IVD) Market

34. Recent Developments In The Cancer In Vitro Diagnostics (IVD) Market

35. Cancer In Vitro Diagnostics (IVD) Market High Potential Countries, Segments and Strategies

  • 35.1 Cancer In Vitro Diagnostics (IVD) Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Cancer In Vitro Diagnostics (IVD) Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Cancer In Vitro Diagnostics (IVD) Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer